Sage Therapeutics, Inc. - Product Pipeline Review - 2016

  • ID: 3846559
  • Company Profile
  • 42 pages
  • Global Markets Direct
1 of 4
Sage Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

‘Sage Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sage Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sage Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sage Therapeutics, Inc.
- The report provides overview of Sage Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sage Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sage Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Sage Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sage Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sage Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Sage Therapeutics, Inc. Snapshot

Sage Therapeutics, Inc. Overview

Key Information

Key Facts

Sage Therapeutics, Inc. - Research and Development Overview

Key Therapeutic Areas

Sage Therapeutics, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Sage Therapeutics, Inc. - Pipeline Products Glance

Sage Therapeutics, Inc. - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Sage Therapeutics, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Sage Therapeutics, Inc. - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Sage Therapeutics, Inc. - Drug Profiles

sepranolone

Product Description

Mechanism of Action

R&D Progress

SAGE-217

Product Description

Mechanism of Action

R&D Progress

SAGE-689

Product Description

Mechanism of Action

R&D Progress

SAGE-105

Product Description

Mechanism of Action

R&D Progress

SAGE-324

Product Description

Mechanism of Action

R&D Progress

SAGE-718

Product Description

Mechanism of Action

R&D Progress

SGE-872

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize NMDA Receptor for Cognitive Disorders

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize NMDA receptor for CNS Disorders

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Modulate GABAA Receptor for CNS Disorders

Product Description

Mechanism of Action

R&D Progress

Sage Therapeutics, Inc. - Pipeline Analysis

Sage Therapeutics, Inc. - Pipeline Products by Target

Sage Therapeutics, Inc. - Pipeline Products by Route of Administration

Sage Therapeutics, Inc. - Pipeline Products by Molecule Type

Sage Therapeutics, Inc. - Pipeline Products by Mechanism of Action

Sage Therapeutics, Inc. - Recent Pipeline Updates

Sage Therapeutics, Inc. - Dormant Projects

Sage Therapeutics, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Sage Therapeutics, Inc., Key Information

Sage Therapeutics, Inc., Key Facts

Sage Therapeutics, Inc. - Pipeline by Indication, 2016

Sage Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Sage Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Sage Therapeutics, Inc. - Phase III, 2016

Sage Therapeutics, Inc. - Phase II, 2016

Sage Therapeutics, Inc. - Phase I, 2016

Sage Therapeutics, Inc. - IND/CTA Filed, 2016

Sage Therapeutics, Inc. - Preclinical, 2016

Sage Therapeutics, Inc. - Discovery, 2016

Sage Therapeutics, Inc. - Pipeline by Target, 2016

Sage Therapeutics, Inc. - Pipeline by Route of Administration, 2016

Sage Therapeutics, Inc. - Pipeline by Molecule Type, 2016

Sage Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016

Sage Therapeutics, Inc. - Recent Pipeline Updates, 2016

Sage Therapeutics, Inc. - Dormant Developmental Projects,2016 39List of Figures

Sage Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016

Sage Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Sage Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Sage Therapeutics, Inc. - Pipeline by Target, 2016

Sage Therapeutics, Inc. - Pipeline by Route of Administration, 2016

Sage Therapeutics, Inc. - Pipeline by Molecule Type, 2016

Sage Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll